Cogent Biosciences, Inc. financial data

Symbol
COGT on Nasdaq
Industry
Pharmaceutical Preparations
Location
275 Wyman Street, 3 Rd Floor, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Unum Therapeutics Inc. (to 10/5/2020), Unum Therapeutics, Inc. (to 3/30/2018)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 848 % -17.3%
Debt-to-equity 17.2 % +7.43%
Return On Equity -70.9 % -12.7%
Return On Assets -60.4 % -11.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 110M shares +28.3%
Common Stock, Shares, Outstanding 110M shares +28.3%
Entity Public Float 968M USD +70.5%
Common Stock, Value, Issued 110K USD +27.9%
Weighted Average Number of Shares Outstanding, Basic 110M shares +27.9%
Weighted Average Number of Shares Outstanding, Diluted 110M shares +27.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 219M USD +35.6%
General and Administrative Expense 41.1M USD +29%
Costs and Expenses 260M USD +34.5%
Operating Income (Loss) -260M USD -34.5%
Nonoperating Income (Expense) 18.1M USD +13.5%
Net Income (Loss) Attributable to Parent -242M USD -36.4%
Earnings Per Share, Basic -2.49 USD/shares -9.21%
Earnings Per Share, Diluted -2.49 USD/shares -9.21%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 97M USD +11.8%
Assets, Current 342M USD +19.4%
Property, Plant and Equipment, Net 7.02M USD -18.8%
Operating Lease, Right-of-Use Asset 20.6M USD -7.27%
Other Assets, Noncurrent 4.86M USD 0%
Assets 384M USD +8.04%
Accounts Payable, Current 15.1M USD +52.6%
Employee-related Liabilities, Current 7.73M USD +31.7%
Liabilities, Current 53M USD +52.8%
Operating Lease, Liability, Noncurrent 16.3M USD -8.53%
Liabilities 69.4M USD +32%
Accumulated Other Comprehensive Income (Loss), Net of Tax 896K USD
Retained Earnings (Accumulated Deficit) -792M USD -44.1%
Stockholders' Equity Attributable to Parent 315M USD +3.88%
Liabilities and Equity 384M USD +8.04%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -52.5M USD -32.9%
Net Cash Provided by (Used in) Financing Activities 214M USD +48003%
Net Cash Provided by (Used in) Investing Activities 1.04M USD -98.3%
Common Stock, Shares Authorized 300M shares +100%
Common Stock, Shares, Issued 110M shares +28.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 163M USD +681%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 97M USD +11.8%
Deferred Tax Assets, Valuation Allowance 157M USD +75.4%
Operating Lease, Liability 18.9M USD -4.05%
Payments to Acquire Property, Plant, and Equipment 70K USD -93.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -241M USD -35.8%
Lessee, Operating Lease, Liability, to be Paid 28M USD -8.27%
Property, Plant and Equipment, Gross 12M USD +30.8%
Operating Lease, Liability, Current 1.52M USD +13.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.84M USD +2.19%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.78M USD +9.28%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.16M USD -13.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.7M USD -5.07%
Deferred Tax Assets, Operating Loss Carryforwards 48M USD +32.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.13M USD -20.9%
Operating Lease, Payments 873K USD +13.1%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 38.6M USD +44%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%